Start here if you're new
what it is
Jupiter Neuroscience is a 4-person biotech trying to turn one resveratrol formula into drugs and supplements.
how it gets paid
Product revenue is effectively $0—pre-revenue biotech. Do not assign 20% of sales to a pipeline row; use R&D focus instead.
what just happened
JUNS lost $0.18 a share in the latest quarter, and trailing EPS sits at -$0.28.
At a glance
n/a balance sheet
-$0.08 fy2024 eps est
~$15M market cap
small cap
NYSE
What they do
Jupiter Neuroscience is a 4-person biotech trying to turn one resveratrol formula into drugs and supplements.
You are betting on one formula, JOTROL, doing two jobs. The company says it has improved bioavailability, which means more of the active ingredient gets into your body. One path is a Phase IIa Parkinson's program. The other is Nugevia, its consumer line.
How they make money
~$0
product revenue · bars = program attention mix, not dollars
JOTROL platform
focus
lead
Nugevia consumer line
focus
consumer
Parkinson's program
focus
clinical
Alzheimer's program
focus
early
Rare-disease basket
focus
pipeline
The products that matter
lead clinical program
Resveratrol Platform
core equity story
At ~$15M market cap and ~$1.10 share price in the hero strip, this program is still doing almost all of the valuation work.
one bet
balance sheet survival
cash runway
the real operating metric
with no revenue disclosed here and 34.4M shares already outstanding, cash is not bookkeeping — it is permission to keep going without painful dilution.
staying alive
future pipeline claim
platform optionality
second shot on goal
every biotech says it is more than one asset. at roughly a $15M equity value, investors should demand proof before paying for optionality that is still mostly a slide.
prove it
Key numbers
-$0.08
2024 EPS est (loss)
A negative EPS estimate means the business is still not paying its own bills from operations.
4
employees
A 4-person company has very little room for mistakes, delays, or extra payroll.
$15M
market cap
That is a tiny valuation for a drug company, so one trial result can move the stock hard.
$0M
TTM revenue
No revenue means every milestone matters more than sales do right now.
Financial health
n/a
strength
- balance sheet grade n/a
n/a — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for JUNS right now.
source: institutional data · return history unavailable
What just happened
loss Q · check vs est.
JUNS lost $0.18 a share in the latest quarter, and trailing EPS sits at -$0.28.
EDGAR gives no revenue number for the period. Yahoo Finance shows trailing revenue at $0M, so the quarter reads like pure expense with no sales buffer. -$0.18 Q vs strip ~-$0.08 FY2024 EPS est. is not the same window—confirm before tagging beat/miss.
$0M
revenue
-$0.18
eps
n/a
n/a
the number that mattered
The -$0.18 quarterly EPS matters because it shows the company is still posting losses without a revenue base.
source: EDGAR and Yahoo Finance consensus, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk here is lead-program failure in the resveratrol platform. This is not a diversified biotech. It is a very small public company with one narrative carrying most of the weight.
med
the lead program disappoints
If the resveratrol thesis breaks, the equity story breaks with it. There is no disclosed revenue base here to soften the blow.
with a recent market cap of $14.6M, a failed lead asset can erase a large share of what investors thought they owned.
med
cash needs force dilution
Early-stage biotech lives on financing calendars. If milestones slip while the stock is around $0.42, new capital gets more expensive for existing holders.
34.4M shares are already outstanding. More shares can keep the company alive while shrinking your claim on any future upside.
med
thin coverage keeps the stock unstable
There is no xvary composite score here because outside data are sparse. Thin coverage means price discovery can get sloppy fast.
a $14.6M micro-cap with limited institutional attention can move hard on small volume, loose expectations, or delayed communication.
these risks stack, not subtract. A weak data update plus a financing need would pressure nearly all of the current $14.6M equity value at the same time.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
the next milestone date
If management starts moving dates without replacing them with concrete new ones, the market usually hears the quiet part.
trend
whether $0.42 was panic or repricing
A bounce is noise. A sustained rebuild in market value would tell you investors think the science still has a path.
risk
dilution pressure
At 34.4M shares outstanding, a financing is not a footnote. Watch the share count as closely as the trial language.
metric
evidence of a second asset
If this really is a platform and not one program in a trench coat, management needs to show it with specifics, not branding.
Analyst rankings
short-term outlook
unclear
coverage is thin and the price action has done the talking. in human-speak, there is no clean outside consensus to hide behind.
risk profile
very high
a $14.6M clinical biotech with no revenue base will trade on binary outcomes, financing terms, and patience running out.
chart momentum
broken
the move from $1.10 to $0.42 over the available dates says this is a catalyst stock, not a smooth trend story.
earnings predictability
40 / 100
that low score fits the setup. when the underlying business is still forming, accounting outputs tell you less than milestones do.
source: institutional data
Institutional activity
institutional ownership data for JUNS is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$1
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive